Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.97% | 0.57% | -0.65% | -17.65% | -7.22% |
| Total Depreciation and Amortization | 137.50% | -4.95% | -3.81% | -55.51% | 129.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.40% | -4.56% | 4.18% | 8.68% | 37.50% |
| Change in Net Operating Assets | -315.87% | 87.13% | -85.48% | 30.37% | -23.29% |
| Cash from Operations | -24.61% | 1.81% | -13.28% | -19.25% | -8.42% |
| Capital Expenditure | -- | -- | -- | 100.00% | -900.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -423.30% | 147.82% | -167.31% | 197.18% | -65.24% |
| Cash from Investing | -423.30% | 147.82% | -167.31% | 202.31% | -65.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.99% | 494.96% | 260.88% | 1,823.36% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.99% | 494.96% | 260.88% | 1,823.36% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.23% | 408.37% | -282.13% | 328.33% | -146.67% |